{"version":"1.0","type":"link","title":"Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.","author_name":"Lopez JS 외","author_url":"https://prs-insight.online/author/Lopez%20JS","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/95111","thumbnail_width":1200,"thumbnail_height":630}